A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants

Grants and Contracts Details

StatusActive
Effective start/end date8/10/202/20/23

Funding

  • Merck Sharp & Dohme Corporation: $179,224.00